구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | TNFi (TNFi, Tumor Necrosis Factor inhibitor, TNFi (Tumor Necrosis Factor inhibitor) medication) Bristol-Myers Squibb·Polyarticular Course Juvenile Idio… 134 trials |
|---|---|
Overview Program | TNFi (Tumor Necrosis Factor inhibitor) medication |
Overview Company | Bristol-Myers Squibb |
Overview Modality | ANTIBODY |
Overview Target | Polyarticular Course Juvenile Idiopathic |
Overview Indication | Polyarticular Course Juvenile Idiopathic Arthritis (JIA) |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Mechanism | Targeting specific cytokine pathway |
MoA Biomarker | biomarker for the effectiveness of mainly abatacept and other biologic disease-modifying antirheumatic drugs |
PK/PD Species | Mouse, Rat, Human |
PK/PD Animal (cat.) | Human, Mouse, Rat, In vitro |
PK/PD Experiment | pd |
Toxicology Species | Mouse, Rat, Human |
Toxicology Animal (cat.) | Human, Mouse, Rat, In vitro |
Toxicology Major finding | Whole-blood coagulation and platelet dynamics identify differential prothrombotic states in patients with rheumatoid arthritis treated with JAK or TNF-ɑ inhibitors.. Rheumatoid arthritis (RA) is associated with inflammation-driven hypercoagulability and increased venous thromboembolic risk. Post hoc analyses of safety trials have raised concerns regarding a potential differential thrombotic … |
Clinical Safety signal | Whole-blood coagulation and platelet dynamics identify differential prothrombotic states in patients with rheumatoid arthritis treated with JAK or TNF-ɑ inhibitors.. Rheumatoid arthritis (RA) is associated with inflammation-driven hypercoagulability and increased venous thromboembolic risk. Post hoc analyses of safety trials have raised concerns regarding a potential differential thrombotic … |
Clinical Selected reported efficacy | 27.5% |
Clinical Result source | ClinicalTrials.gov NCT02015520 |
Clinical Program phase | PHASE_3 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT02015520 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | TNFi (TNFi, Tumor Necrosis Factor inhibitor, TNFi (Tumor Necrosis Factor inhibitor) medication) Bristol-Myers Squibb·Polyarticular Course Juvenile Idio… 134 trials |
|---|---|
Overview Program | TNFi (Tumor Necrosis Factor inhibitor) medication |
Overview Company | Bristol-Myers Squibb |
Overview Modality | ANTIBODY |
Overview Target | Polyarticular Course Juvenile Idiopathic |
Overview Indication | Polyarticular Course Juvenile Idiopathic Arthritis (JIA) |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Mechanism | Targeting specific cytokine pathway |
MoA Biomarker | biomarker for the effectiveness of mainly abatacept and other biologic disease-modifying antirheumatic drugs |
PK/PD Species | Mouse, Rat, Human |
PK/PD Animal (cat.) | Human, Mouse, Rat, In vitro |
PK/PD Experiment | pd |
Toxicology Species | Mouse, Rat, Human |
Toxicology Animal (cat.) | Human, Mouse, Rat, In vitro |
Toxicology Major finding | Whole-blood coagulation and platelet dynamics identify differential prothrombotic states in patients with rheumatoid arthritis treated with JAK or TNF-ɑ inhibitors.. Rheumatoid arthritis (RA) is associated with inflammation-driven hypercoagulability and increased venous thromboembolic risk. Post hoc analyses of safety trials have raised concerns regarding a potential differential thrombotic … |
Clinical Safety signal | Whole-blood coagulation and platelet dynamics identify differential prothrombotic states in patients with rheumatoid arthritis treated with JAK or TNF-ɑ inhibitors.. Rheumatoid arthritis (RA) is associated with inflammation-driven hypercoagulability and increased venous thromboembolic risk. Post hoc analyses of safety trials have raised concerns regarding a potential differential thrombotic … |
Clinical Selected reported efficacy | 27.5% |
Clinical Result source | ClinicalTrials.gov NCT02015520 |
Clinical Program phase | PHASE_3 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT02015520 |
추천 비교
추천 비교